U.S. Markets close in 3 hrs 42 mins
Stocks To Watch

Target soars on sales rebound, Urban Outfitters surges on beat, Apple eyes Hollywood

AcelRx Pharmaceuticals, Inc. (ACRX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.025+0.050 (+1.681%)
As of 12:18PM EDT. Market open.
People also watch
AVEOALIMFOLDECYTANTH
Full screen
Previous Close2.975
Open2.950
Bid3.000 x 6300
Ask3.050 x 103700
Day's Range2.950 - 3.050
52 Week Range1.950 - 4.080
Volume178,069
Avg. Volume1,051,514
Market Cap137.28M
Beta3.03
PE Ratio (TTM)-2.87
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents4 days ago

    Edited Transcript of ACRX earnings conference call or presentation 1-Aug-17 12:30pm GMT

    Q2 2017 AcelRx Pharmaceuticals Inc Earnings Call

  • SmarterAnalyst14 days ago

    AcelRx Pharmaceuticals Inc (ACRX) Could Face Opioid Heat from FDA with Zalviso, Worries Roth Capital

    Roth Capital Michael Higgins believes this does not bode well for ACRX even in the wake of EU post-approval, concerned that 14 months following the FDA issuing its CRL, "[...] the FDA's heightened sensitivity to the opioid crisis is likely to prevent Zalviso’s approval." In fact, Higgings anticipates "today's FDA may have a problem" here, and asserts that this "overshadowed" earnings. "With FDA skating on thin ice, in our view, we believe Zalviso's NDA as too heavy for the agency to bear," contends Higgins, elaborating, "In our modeling we have dropped our probability of Zalviso’s U.S. approval from 25% to 0%. "We believe Zalviso's 2015 CRL has been anchoring a cloud over ACRX shares, as investor attention on Dsuvia has been slow to develop," surmises the analyst.

  • Associated Press15 days ago

    AcelRx Pharmaceuticals reports 2Q loss

    On a per-share basis, the Redwood City, California-based company said it had a loss of 29 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...